Giles Major
YOU?
Author Swipe
View article: Alternative Gastrointestinal Conditions Identified in Patients Meeting Rome IV Criteria for Irritable Bowel Syndrome or Functional Diarrhea Referred to Secondary Care: A Prospective Study
Alternative Gastrointestinal Conditions Identified in Patients Meeting Rome IV Criteria for Irritable Bowel Syndrome or Functional Diarrhea Referred to Secondary Care: A Prospective Study Open
Introduction: Organic gastrointestinal (GI) disorders can be missed in individuals with irritable bowel syndrome (IBS). This study investigated the frequency of organic disorders in patients with diarrhea-predominant IBS or functional diar…
View article: A focus group study to assess perspectives of patients with irritable bowel syndrome on human milk oligosaccharides and lifestyle insights
A focus group study to assess perspectives of patients with irritable bowel syndrome on human milk oligosaccharides and lifestyle insights Open
Objective To explore the impact of Irritable Bowel Syndrome (IBS) on quality of life (QoL) measures, with specific focus on symptoms experienced and their impact upon diet, lifestyle, and mood. Insights into triggers of IBS flare-ups and t…
View article: CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden
CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden Open
View article: An <i>in vitro</i> batch culture study to assess the fermentation of human milk oligosaccharides by faecal microbiota from healthy and irritable bowel syndrome stool donors
An <i>in vitro</i> batch culture study to assess the fermentation of human milk oligosaccharides by faecal microbiota from healthy and irritable bowel syndrome stool donors Open
This study explored the effects of different human milk oligosaccharides (HMOs), solely and in combination, on gut microbiota composition and metabolic activity (organic acid production), using anaerobic in vitro batch culture fermenters. …
View article: A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)
A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI) Open
View article: The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes Open
Background To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc). Methods SSc patients from the Australian Scleroderma Cohort …
View article: Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis Open
View article: A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study. Open
Background People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve …
View article: Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis Open
Background There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elex…
View article: A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes.
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. Open
Background People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve …
View article: Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome Open
People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF. However, there is a paucity of kn…
View article: Use of fiber-containing enteral formula in pediatric clinical practice: an expert opinion review
Use of fiber-containing enteral formula in pediatric clinical practice: an expert opinion review Open
The current evidence supports using fibers in enteral formulas as first-line nutrition therapy. Dietary fibers should be considered for all patients receiving enteral nutrition and can be slowly introduced from six months of age. Fiber pro…
View article: EPS5.03 Elexacaftor/Tezacaftor/Ivacaftor for 76 weeks is associated with a reduced orocaecal transit time: the GIFT-CF3 extension study
EPS5.03 Elexacaftor/Tezacaftor/Ivacaftor for 76 weeks is associated with a reduced orocaecal transit time: the GIFT-CF3 extension study Open
View article: Postinfective bowel dysfunction following <i>Campylobacter enteritis</i> is characterised by reduced microbiota diversity and impaired microbiota recovery
Postinfective bowel dysfunction following <i>Campylobacter enteritis</i> is characterised by reduced microbiota diversity and impaired microbiota recovery Open
Objectives Persistent bowel dysfunction following gastroenteritis (postinfectious (PI)-BD) is well recognised, but the associated changes in microbiota remain unclear. Our aim was to define these changes after gastroenteritis caused by a s…
View article: A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome
A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome Open
Treatable gastrointestinal disorders in patients with symptoms typical for irritable bowel syndrome (IBS) may be overlooked. The prevalence of five gastrointestinal conditions—bile acid diarrhoea (BAD), carbohydrate malabsorption (CM), mic…
View article: Core outcome set for clinical studies of postoperative ileus after intestinal surgery
Core outcome set for clinical studies of postoperative ileus after intestinal surgery Open
Postoperative ileus is a common and distressing complication after intestinal surgery1. It presents clinically as impairment of intestinal motility, characterized by abdominal pain, vomiting, and delayed recovery of defaecatory function. F…
View article: Impact of home parenteral nutrition on family members: A national multi-centre cross-sectional study
Impact of home parenteral nutrition on family members: A national multi-centre cross-sectional study Open
View article: Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis
Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis Open
Alterations in gut function and transit resultant of CF disease are associated with the gut microbiota composition, notably the satellite taxa. Delayed transit in the small intestine might allow for the expansion of satellite taxa resultin…
View article: 465: Intestinal function and transit relates to microbial dysbiosis in the CF gut
465: Intestinal function and transit relates to microbial dysbiosis in the CF gut Open
View article: Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis
Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis Open
Background Most people with cystic fibrosis (pwCF) suffer from gastrointestinal symptoms and are at risk of gut complications. Gut microbiota dysbiosis is apparent within the CF population across all age groups, with evidence linking dysbi…
View article: Psyllium reduces inulin-induced colonic gas production in IBS: MRI and<i>in vitro</i>fermentation studies
Psyllium reduces inulin-induced colonic gas production in IBS: MRI and<i>in vitro</i>fermentation studies Open
Objective Health-promoting dietary fibre including inulin often triggers gastrointestinal symptoms in patients with IBS, limiting their intake. Our aim was to test if coadministering psyllium with inulin would reduce gas production. Design…
View article: Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis
Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis Open
We were unable to determine whether one dosing schedule for PERT is better than another since we identified no eligible RCTs. While the introduction of PERT to people with CF can improve their nutritional status, there are a limited number…
View article: Systematic Review and Meta-Analysis: What is the Prevalence of Non-Malignant, Organic Gastrointestinal Disorders Misdiagnosed as Lrritable Bowel Syndrome?
Systematic Review and Meta-Analysis: What is the Prevalence of Non-Malignant, Organic Gastrointestinal Disorders Misdiagnosed as Lrritable Bowel Syndrome? Open
Introduction Treatable gastrointestinal disorders in patients with symptoms typical for irritable bowel syndrome (IBS) may be overlooked. The prevalence of five gastrointestinal conditions - bile acid diarrhoea (BAD), carbohydrate malabsor…
View article: Psyllium reduces insulin-induced colonic gas production in irritable bowel syndrome: MRI and in vitro fermentation studies
Psyllium reduces insulin-induced colonic gas production in irritable bowel syndrome: MRI and in vitro fermentation studies Open
Objective: Health promoting dietary fibre including inulin often triggers gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), limiting their intake. Our aim was to test if co-administering psyllium with inulin would …
View article: Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls
Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls Open
Cystic fibrosis (CF) is a genetic disease affecting mucosal secretions. Most patients experience digestive symptoms, but the mechanisms are incompletely understood. Here we explore causes and consequences of slower gastrointestinal transit…
View article: Supplementary Metadata
Supplementary Metadata Open
Supplementary metadata utilised for the ordination approach applied to the microbiota data in this study.Table S1 - Dietary information obtained from study participants.Table S2 - Magnetic resonance imaging (MRI) metri…
View article: P341 Systematic review and meta-analysis: prevalence of organic gastrointestinal conditions in patients with irritable bowel syndrome
P341 Systematic review and meta-analysis: prevalence of organic gastrointestinal conditions in patients with irritable bowel syndrome Open
Introduction Studies have suggested that organic diseases particularly bile acid diarrhoea/malabsorption, carbohydrate malabsorption, microscopic colitis, pancreatic exocrine insufficiency and small intestinal bacterial overgrowth, may be …
View article: O62 Psyllium reduces colonic hydrogen production following ingestion of inulin in irritable bowel syndrome
O62 Psyllium reduces colonic hydrogen production following ingestion of inulin in irritable bowel syndrome Open
Introduction Patients with irritable bowel syndrome (IBS) often develop symptoms of gas and flatulence after intake of the prebiotic inulin, leading to dietary avoidance that may have deleterious effects on gut microbiota. Our aim was to d…
View article: Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review
Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review Open
Background Patients with cystic fibrosis (CF) are characterised by abnormalities of the intestinal tract relating to gut motility and physiological issues, with daily symptoms of disease including abdominal pain, flatulence, bloating, and …
View article: Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging Open